VNDA catalyst calendar

Vanda Pharmaceuticals Inc.

Upcoming catalysts
13
Cash runway
3.3 months
Cash & investments
$56M
Phase 3 programs
22

Vanda Pharmaceuticals Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension on October 15, 2026. There are 13 upcoming events on record.

Cash runway is approximately 3.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 58 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Trial Milestone Phase 2
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
December 1, 2026 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Trial Milestone Phase 3
December 15, 2026 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder Trial Milestone Phase 3
March 15, 2027 Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient Trial Milestone Phase 1/Phase 2
September 30, 2027 Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Trial Milestone Phase 3
November 15, 2027 Randomized Withdrawal Study in Patients With Schizophrenia Trial Milestone Phase 3
November 15, 2027 Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Trial Milestone Phase 3
December 15, 2027 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Trial Milestone Phase 1
March 15, 2028 Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Trial Milestone Phase 3
August 15, 2028 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Trial Milestone Phase 3
December 31, 2028 Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Trial Milestone Phase 4
April 15, 2029 Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Trial Milestone Phase 3

Track VNDA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open VNDA in the tracker

Recent history

DateEventTypePhase
September 15, 2026 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye Trial Milestone Phase 2
September 15, 2026 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Trial Milestone Phase 2
September 4, 2026 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Trial Milestone Phase 3
August 5, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 Quarterly results filed (8-K) Earnings —
April 22, 2026 8-K filed: Leadership change Corporate —
April 2, 2026 8-K filed: Leadership change Corporate —
March 10, 2026 8-K filed: Reg FD disclosure Filing —
February 23, 2026 8-K filed: Other event Filing —
February 19, 2026 8-K filed: Leadership change Corporate —
February 11, 2026 Quarterly results filed (8-K) Earnings —
January 8, 2026 8-K filed: Other event Filing —
December 31, 2025 8-K filed: Other event Filing —
December 15, 2025 Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Trial Milestone Phase 3
December 4, 2025 8-K filed: Other event Filing —
November 28, 2025 8-K filed: Other event Filing —
October 29, 2025 Quarterly results filed (8-K) Earnings —
October 6, 2025 A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use Trial Milestone Phase 2
October 1, 2025 8-K filed: Other event Filing —
July 31, 2025 Quarterly results filed (8-K) Earnings —
June 30, 2025 Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant Trial Milestone Phase 3
May 7, 2025 Quarterly results filed (8-K) Earnings —
February 21, 2025 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis Trial Milestone Phase 3
October 24, 2024 Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions Trial Milestone Phase 1
July 12, 2024 Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Trial Milestone Phase 3
April 6, 2024 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Trial Milestone Phase 3
August 17, 2023 Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Trial Milestone Phase 3
April 1, 2023 Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Trial Milestone Phase 3
December 27, 2022 Food Effect Study of VHX-896 in Healthy Volunteers Trial Milestone Phase 1
September 7, 2022 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.